REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Description

The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.

Conditions

Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic

Study Overview

Study Details

Study overview

The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.

Reducing Exsanguination Via In-Vivo Expandable Foam

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Condition
Hemorrhagic Shock
Intervention / Treatment

-

Contacts and Locations

Cincinnati

University of Cincinnati, Cincinnati, Ohio, United States, 45219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Estimated age of 15 years or older (or subject weight estimated at greater than 50 kg if age is unknown)
  • 2. Emergent, exsanguinating hemorrhage, from abdominal source as defined by:
  • * Class III or IV hemorrhagic shock or
  • * Assessment of Blood Consumption (ABC) score ≥ 2
  • 3. Confirmation of abdominal hemorrhage by:
  • * Direct visualization or
  • * Positive Focused Assessment with Sonography in Trauma (FAST) or
  • * Diagnostic Peritoneal Aspiration (DPA)
  • 4. No other known, uncontrolled active sources of hemorrhage
  • 5. Subject is intubated and sedated per local guidelines
  • 6. Decision to administer foam is made within 30 minutes of admission to the emergency department.
  • 7. Decision made to proceed to emergent laparotomy made within 30 minutes of admission to the emergency department.
  • 8. Definitive surgical care is expected to occur within three hours of foam deployment
  • 9. Subject must also be receiving concurrent transfusion of fluids or blood products.
  • 10. Known or suspected major diaphragm injury
  • 11. Known or suspected untreated pneumothorax
  • 12. Known or suspected untreated hemothorax
  • 13. Known or suspected blunt or penetrating cardiac or thoracic aortic trauma
  • 14. Traumatic brain injury resulting in decapitation, visible brain matter or considered non- survivable based on initial physical exam
  • 15. Received greater than five consecutive minutes of cardiopulmonary resuscitation in the pre-emergency department setting
  • 16. Patients with Pulseless Electrical Activity
  • 17. Known allergy to isocyanate
  • 18. Known or suspected pregnancy
  • 19. History of prior abdominal surgery or evidence of abdominal surgery (scars)
  • 20. Disrupted abdominal wall that, in the opinion of the investigator would preclude ResQFoam from being adequately contained within the abdominal cavity
  • 21. Subject in whom the abdominal aortic junctional tourniquet (AAJT) or Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) techniques have been used
  • 22. Known Prisoners
  • 23. Subjects with burns \> 20% of total body surface area
  • 24. Subject/legally authorized representative/subject family member purposefully opted out of participation in the study
  • 25. Known Do Not Resuscitate order (DNR) or Physician Orders for Life Sustaining Treatment (POLST)
  • 26. Known enrollment in another randomized, interventional study

Ages Eligible for Study

15 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Arsenal Medical, Inc.,

Timothy Pritts, MD, PRINCIPAL_INVESTIGATOR, University of Cincinnati

Study Record Dates

2025-07-28